BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression-Reference-Cited by-同舟云学术

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

Published:2016-09 Issue:11 Volume:16 Page:2829-2837
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Zhu Hengrui,Bengsch Fee,Svoronos Nikolaos,Rutkowski Melanie R.,Bitler Benjamin G.,Allegrezza Michael J.,Yokoyama Yuhki,Kossenkov Andrew V.,Bradner James E.,Conejo-Garcia Jose R.,Zhang Rugang

Funder

NIH/National Cancer Institute

U.S. Department of Defense

Jayne Koskinas & Ted Giovanis Breast Cancer Research Consortium

Cancer Center Support Grant

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference23 articles.

1. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction;Abiko;Clin. Cancer Res.,2013

2. Big opportunities for small molecules in immuno-oncology;Adams;Nat. Rev. Drug Discov.,2015

3. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma;Baratta;Proc. Natl. Acad. Sci. USA,2015

4. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses;Belkina;J. Immunol.,2013

5. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers;Bitler;Nat. Med.,2015

Cited by 341 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1;Advanced Science;2024-09-04

2. Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells;Molecular Biology Reports;2024-09-04

3. Ring Transformation of Cyclopropenes to Benzo‐Fused Five‐Membered Oxa‐ and Aza‐Heterocycles via a Formal [4+1] Cyclization;Advanced Science;2024-08-29

4. Bacterial and cancerous cell membrane fused liposome coordinates with PD-L1 inhibitor for cancer immunotherapy;Nano Research;2024-08-03

5. Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor);2024-07-29